CMV serostatus is associated with improved survival and delayed toxicity onset following anti-PD-1 checkpoint blockade
A conversation with Ben Fairfax about the recent article: CMV serostatus is associated with improved survival and delayed toxicity onset following anti-PD-1 checkpoint blockade.